InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
68,040.36
(
0.35%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: pharma11 post# 1605

Thursday, 09/21/2006 5:06:16 PM

Thursday, September 21, 2006 5:06:16 PM

Post# of 4764
Not sure pharma. I just came across this patent. The more I look at patents/IP issues, the more confused I get. Imclone's IP position has not deterred others from developing anti-EGFR antibodies. This is in contrast to Imclone's IP position on anti-VEGFR antibodies. Imclone's strong IP position enabled them to gain rights to the UCB antibody in addition to Imclone's anti-VEGFR antibody. Any comments on what Imclone did right with anti-VEGFR (that they did not do with EGFR)?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up